ClinicalTrials.gg
Not yet recruitingNCT07816770MANTIS-RCCUpdated Sep 14, 2026

MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas

A Phase 2 interventional study of Toripalimab and Axitinib in Metastatic Non-Clear Cell Renal Cell Carcinoma and Metastatic Renal Medullary Carcinomas, sponsored by Fudan University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing toripalimab in Carcinoma, Renal Cell — 8 open to participants now, 11 under way, 1 of them phase 3. toripalimab · Carcinoma, Renal Cell.

Planned enrollment
8th of 13
30 · median 40
Started
2026
with 4 others
Phase 2
11 of 13
6 open now
Primary completion
2027-12
later than 4 of 10 live
Registered
13th of 13
by date
Lead sponsor
2 of 13
Fudan University

Among the 13 studies testing toripalimab in Carcinoma, Renal Cell, this one is the 8th largest by planned enrollment, is one of 5 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 13th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

8 of the 13 studies testing toripalimab in Carcinoma, Renal Cell are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing toripalimab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This Phase II study will evaluate toripalimab plus axitinib in adults with previously untreated, synchronous metastatic non-clear cell renal cell carcinoma and renal medullary carcinomas whose primary kidney tumor remains in place and whose baseline tumor biopsy contains a tertiary lymphoid structure. All participants will receive toripalimab and axitinib for approximately 12 weeks. At Week 12, an independent multidisciplinary team will review treatment response, overall disease burden, fitness for surgery, technical resectability, and participant preference. Deferred cytoreductive nephrectomy will be performed only when it has an independent clinical indication; it is not mandatory and is not assigned at random. Participants who do not undergo surgery will remain in the study for clinical follow-up. The study will estimate the proportion of eligible surgical participants who remain free of progression or death 24 weeks after surgery and will evaluate whether the functional state of tertiary lymphoid structures in the treated primary tumor is associated with control of residual metastatic disease. Peripheral blood will be used to track T-cell and B-cell receptor clonotypes. Postoperative blood for this purpose will be collected only at 3 months, and disease progression.

Read the detailed description

MANTIS-RCC is an investigator-initiated, prospective, open-label, single-center, single-arm Phase II clinical and translational study. Candidate participants will undergo image-guided core biopsy of the intact primary renal tumor. Central pathology review will confirm non-clear cell renal cell carcinoma and renal medullary carcinoma, exclude any clear cell component, and confirm biopsy-detectable tertiary lymphoid structures using a prespecified morphologic and immunophenotypic definition.

Enrolled participants will receive toripalimab 240 mg by intravenous infusion every 3 weeks plus axitinib 5 mg orally twice daily for four planned cycles, corresponding to approximately 12 weeks of induction therapy. Imaging is required at baseline, Week 6, and Week 12. In the absence of progression or unacceptable toxicity, systemic therapy may continue after Week 12 and after surgery. Toripalimab may continue for up to approximately 2 years, and axitinib may continue until progression, unacceptable toxicity, withdrawal of consent, or an investigator decision that treatment should stop.

At Week 12, a multidisciplinary team that does not use the translational assay results will determine whether deferred cytoreductive nephrectomy is clinically appropriate. The decision will consider systemic disease control, performance status, operative risk, resectability of the primary tumor, metastatic burden, the clinical purpose of surgery, and participant preference. Surgery will not be performed solely to obtain research tissue. Participants with rapid progression, organ-threatening disease, unacceptable surgical risk, or a need to change systemic therapy will not undergo elective cytoreductive nephrectomy but will remain in the intention-to-treat clinical cohort.

The main postoperative analysis population will include participants who undergo protocol-defined deferred cytoreductive nephrectomy, have at least one measurable metastatic lesion that is not removed or locally treated at surgery, and are expected to resume the same systemic regimen. The surgery date is the landmark for postoperative time-to-event outcomes. Imaging obtained within 14 days before surgery provides the reference metastatic burden; imaging at 4 to 6 weeks after surgery confirms postoperative status but does not restart the progression-free survival clock.

The translational program integrates treated primary-tumor tissue, longitudinal imaging, and immune-repertoire measurements. The postoperative primary tumor will be used to construct a patient-level TLS Functional State Score. TCR sequencing is the primary repertoire analysis and BCR sequencing is supportive. Peripheral blood collected before surgery may include baseline, Week 3, Week 6, Week 12, and the day of surgery. After surgery, peripheral blood for TCR/BCR analysis will be collected only at Month 3, Month 6, and disease progression. The progression sample should be collected before a new systemic or local treatment when clinically feasible. The Month 3 samples will be used to characterize persistence of prespecified TLS-associated clonotypes; the progression sample will characterize loss, re-expansion, and newly detectable clonotypes.

The study is estimation-oriented. Thirty participants are planned. Enrollment may expand to a maximum of 40 only if an independent review confirms acceptable safety and feasibility and fewer than 20 participants are available for the postoperative residual-metastasis primary analysis, with ethics approval before expansion. The study does not test whether cytoreductive nephrectomy improves survival and does not include a TLS-negative comparison group or a randomized no-surgery control.

03

Conditions studied

  • Metastatic Non-Clear Cell Renal Cell Carcinoma
  • Metastatic Renal Medullary Carcinomas

Keywords

  • Non-clear cell renal cell carcinoma
  • metastatic renal cell carcinoma
  • tertiary lymphoid structures
  • toripalimab
  • axitinib
  • deferred cytoreductive nephrectomy
  • Metastatic Renal Medullary Carcinomas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older and able to provide written before any study-specific procedure.
  • Newly diagnosed advanced renal cell carcinoma or renal medullary carcinoma with no prior systemic anticancer therapy for advanced disease and with the primary renal tumor still in place.
  • Central pathology review of a core of the primary renal tumor confirms non-clear cell renal cell carcinoma and renal medullary carcinoma under the 2022 World Health Organization classification and finds no clear cell component. Eligible entities include papillary renal cell carcinoma, chromophobe renal cell carcinoma, TFE3-rearranged or TFEB-altered renal cell carcinoma, fumarate hydratase-deficient renal cell carcinoma, succinate dehydrogenase-deficient renal cell carcinoma, ALK-rearranged renal cell carcinoma, and renal cell carcinoma not otherwise specified or unclassified after adequate workup. Sarcomatoid or rhabdoid differentiation is recorded as a feature and is not an independent subtype.
  • Clinical Stage IV disease according to the AJCC 8th edition, with synchronous distant documented by imaging or pathology.
  • At least one version 1.1 measurable metastatic lesion outside the primary renal tumor: longest diameter at least 10 mm for a non-nodal lesion or short axis at least 15 mm for a lymph node.
  • If deferred cytoreductive nephrectomy is anticipated, the investigator expects that at least one measurable metastatic lesion can remain for longitudinal observation; clinically necessary local treatment must not be delayed for research purposes.
  • Primary-tumor biopsy is adequate for clinical diagnosis, subtype confirmation, required immunohistochemistry or molecular testing, and central TLS assessment, and meets the protocol definition of TLS positivity.
  • TLS positivity requires at least one organized lymphoid aggregate in or near viable tumor, with a recognizable CD20-positive B-cell zone adjacent to or surrounded by a CD3-positive T-cell area, and with organization exceeding scattered lymphocytes or a nonspecific small aggregate.
  • performance status of 0 or 1 and estimated of at least 6 months.
  • Adequate hematologic, hepatic, renal, thyroid, and coagulation function according to institutional laboratory requirements and the current prescribing information for the study drugs.
  • Blood pressure is controlled with or without medication, and baseline proteinuria is acceptable for axitinib treatment in the investigator's judgment.
  • Participants of agree to use effective as required by the current prescribing information and institutional policy.
  • Agreement to provide baseline tumor tissue, serial imaging, and protocol-required blood samples. Refusal of an optional early or progression biopsy or optional additional omics testing does not exclude participation.

Exclusion criteria

Exclusion Criteria:

  • Need for immediate surgery or local intervention for uncontrolled bleeding, infection, urinary obstruction, pain, renal failure, or another emergency that prevents safe completion of induction systemic therapy.
  • Rapidly life-threatening disease requiring immediate radiotherapy, surgery, or another local treatment before study treatment.
  • Active central nervous system metastases with unstable symptoms. Participants with locally treated, stable disease who are off or receiving a stable physiologic dose may be considered by the multidisciplinary team.
  • Prior organ transplantation or active disease requiring systemic therapy. Physiologic hormone replacement or local therapy may be permitted.
  • History of life-threatening immune-related toxicity from prior , anti-PD-L1, or anti-CTLA-4 therapy.
  • Uncontrolled hypertension; cardiovascular disease; recent major arterial or venous thrombosis; active bleeding; a lesion with high bleeding risk; or an uncorrectable coagulation abnormality.
  • Clinically significant proteinuria, uncontrolled thyroid dysfunction, severe hepatic or renal impairment, or another condition that makes toripalimab plus axitinib unacceptably risky.
  • Active infection requiring systemic treatment. Known active , , or infection is evaluated according to institutional infectious-disease policy and protocol-defined risk assessment.
  • Pregnancy or breastfeeding.
  • Another active within 5 years, except an adequately treated malignancy with very low recurrence risk, such as selected carcinoma in situ or basal or squamous cell skin cancer, as determined by the investigator.
  • Severe to either study drug or its .
  • Inability, in the investigator's judgment, to comply with visits, oral treatment, blood-pressure monitoring, or imaging follow-up.
  • No reasonable possibility of entering the planned deferred cytoreductive nephrectomy pathway after induction, or a pathologic subtype for which the clinically preferred immediate treatment is clearly incompatible with the study intervention.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Toripalimab Plus Axitinib With Selective Deferred Cytoreductive Nephrectomy

    Participants receive toripalimab plus axitinib for approximately 12 weeks. At Week 12, an independent multidisciplinary team determines whether deferred cytoreductive nephrectomy is clinically appropriate. Surgery is performed only for participants with clinical benefit, controlled systemic disease, acceptable operative risk, a safely resectable primary tumor, and an independent clinical indication. Participants who do not undergo surgery continue clinically appropriate systemic therapy and study follow-up.

    Drug: Toripalimab · Drug: Axitinib · Procedure: Deferred Cytoreductive Nephrectomy

Interventions

  • Toripalimab 240 mg is administered by intravenous infusion on Day 1 of each 3-week cycle for four planned induction cycles. Dose reduction is not permitted. In participants without progression or unacceptable toxicity, treatment may resume or continue after Week 12 and after surgery for a total duration of up to approximately 2 years, according to the protocol and clinical judgment.

  • Axitinib 5 mg is administered orally twice daily continuously during induction. Dose interruption and reduction to 3 mg twice daily and then 2 mg twice daily are permitted for toxicity. The drug is withheld before elective surgery and restarted after adequate wound healing. It may continue until progression, unacceptable toxicity, withdrawal, or investigator decision.

  • ProcedureDeferred Cytoreductive Nephrectomy

    After Week 12 multidisciplinary review, radical or partial nephrectomy may be performed when clinically indicated and technically appropriate. The surgical approach is selected by the treating surgical team. The procedure is not mandatory, is not randomized, and is never performed solely to obtain research tissue.

06

What researchers measure

Primary outcomes

  1. 24-Week Progression-Free Survival Rate From Deferred Cytoreductive Nephrectomy

    Percentage of participants in the postoperative residual-metastasis primary analysis population who are alive and have not had central RECIST version 1.1 progression by 24 weeks after surgery. Starting a new systemic treatment or receiving local treatment for progression or symptoms in a residual metastatic lesion is counted as an event in the primary strategy.

    Time frame: From the date of deferred cytoreductive nephrectomy through 24 weeks after surgery

  2. Association Between the TLS Functional State Score and 24-Week Postoperative Progression-Free Survival

    The patient-level TLS Functional State Score is derived from the treated primary renal tumor removed at surgery using prespecified pathology and multiplex immunofluorescence features. Association with 24-week postoperative progression-free survival is summarized as the odds ratio per 1-standard-deviation increase in the score, with a 95% confidence interval.

    Time frame: Tumor tissue collected at surgery; clinical outcome assessed through 24 weeks after surgery

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

Of 184 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 98. This study's planned 15 months is below that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 14, 2026
StartEst.
Sep 20, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07816770
Lead sponsor
Fudan University
Responsible party
Ding-Wei Ye (Director of Urology, Fudan University) — Principal investigator
First posted
Sep 14, 2026
Start date
Sep 20, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 14, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Toripalimab · Axitinib

Start the discussion